Author Archives: teralgreen@gmail.com

Uncategorized

CORREA, BERGMAN MEET WITH VA SECY. COLLINS, DISCUSS PSYCHEDELIC-ASSISTED THERAPIES RESEARCH AND ACCESS FOR VETERANS

Posted on by teralgreen@gmail.com
16
Jul

WASHINGTON — Yesterday, Representatives Lou Correa (CA-46) and General Jack Bergman (MI-01), Co-Chairs of the Congressional Psychedelic Advancing Therapies (PATH) Caucus, met with Department of Veterans Affairs (VA) Secretary Doug Collins to discuss psychedelic-assisted therapies research and access for veterans struggling with PTSD and other invisible wounds. Reps. Correa (Middle), Bergman (Right) Pose for Photo […]

Continue reading →
Uncategorized

Can Psychedelics Break Through in Depression? Recent Readouts Leave Investors Wanting More

Posted on by teralgreen@gmail.com
16
Jul

Market reaction to recent readouts from Compass Pathways and Beckley Psytech/atai in treatment-resistant depression speaks to the hurdles psychedelic therapies must clear to quell concerns about commercial viability. Over the past three weeks, psychedelics companies and investors have gotten their first look at two key readouts that could influence momentum in the space. Late last […]

Continue reading →
Uncategorized

Support for psychedelic treatments means full steam ahead at Compass, despite stock drop

Posted on by teralgreen@gmail.com
16
Jul

Though UK-based pharmaceutical company Compass Pathways reached its primary endpoint from its June 23 Phase 3 trial to use synthetic psilocybin for treatment-resistant depression (TRD), investors were seemingly underwhelmed. That same day, shares plunged 46% to a record low of $2.35 a share for the biotech firm. But Kabir Nath, CEO of Compass, defends the […]

Continue reading →
Uncategorized

Texas is the latest state to embrace psychedelic therapy research for mental health treatment

Posted on by teralgreen@gmail.com
16
Jul

Marine Corps veteran Ryan Roberts participates in a mock therapy session in a psilocybin dosing room with assistant professor Amanda Tamman, who is supporting Baylor College of Medicine’s psilocybin study for veterans with PTSD at the Menninger Clinic in Houston. A new Texas law that will provide up to $50 million to study ibogaine reflects […]

Continue reading →
Uncategorized

New Zealand Approved Psychedelic Therapy. He’s the Only Doctor Who Can Do It.

Posted on by teralgreen@gmail.com
16
Jul

Dr. Cameron Lacey has spent years studying how psychedelics might help treat depression and other mood disorders. Last week, he became the first and only psychiatrist in New Zealand allowed to prescribe psilocybin, the hallucinogenic found in “magic mushrooms.” The approval from New Zealand’s health ministry is the latest boost to a growing global movement […]

Continue reading →
Uncategorized

RFK Jr. is bringing psychedelics to the Republican Party

Posted on by teralgreen@gmail.com
15
Jul

Then in August, the Food and Drug Administration rejected drugmaker Lykos Therapeutics’ application to offer ecstasy, alongside therapy, as a treatment for PTSD. FDA advisers worried the company’s researchers were more evangelists than scientists and determined that they’d failed to prove their regimen was either safe or effective. Republicans complained the loudest. “These technocrats think […]

Continue reading →